David Eveleth

Directeur Général chez Trefoil Therapeutics, Inc.

Health Technology

Relations actives

Nom	Sexe	Age	Sociétés liées	Collaboration
Christy Shaffer	M	66	Trefoil Therapeutics, Inc. Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.	-
Benjamin McGraw	M	75	Trefoil Therapeutics, Inc. Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.	7 ans
Ben McGraw	M	-	Trefoil Therapeutics, Inc. Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.	-
Stella M. Robertson	M	-	Trefoil Therapeutics, Inc. Trefoil Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trefoil Therapeutics, Inc. operates as a biotechnology company. The firm develops applications for the eFGFs include regenerative therapies that may address a broad range of ischemic disease, including coronary heart disease, diabetic ulcers, and peripheral artery disease. The company was founded by Ralph Bradshaw, Ken Thomas and Michael Blaber in 2013 and is headquartered in San Diego, CA.	-